Why the study?
Does empagliflozin improve myocardial oxidative stress injury and cardiac fibrosis in diabetic mice?
Does empagliflozin improve myocardial oxidative stress injury and cardiac fibrosis in diabetic mice?
Empagliflozin shows promise for the prevention and treatment of diabetic cardiomyopathy by reducing myocardial oxidative stress and fibrosis in a preclinical model.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating in diabetic mice; leaves open clinical translation to human diabetic cardiomyopathy.
Li et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: